Allophycocyanin apc labeled anti cd34 antibody

AML cell lines used in this study are listed in supplemental Table 1 (available on the Blood Web site). Heparin-anticoagulated peripheral blood (PB) or bone marrow (BM) cells were obtained from 18 newly diagnosed patients with AML (supplemental Table 2) and from 4 healthy adult donors from the Hematology Cell Bank of British Columbia. An additional 33 patients with AML and 6 healthy donors were obtained from The First Affiliated Hospital of Soochow University and the National Clinical Research Center for Hematologic Diseases (supplemental Table 3). Informed consent was obtained in accordance with the Declaration of Helsinki, and all procedures were approved by the Research Ethics Boards at the University of British Columbia and Soochow University. Mononuclear cells were isolated using Lymphoprep (STEMCELL Technologies) density gradient separation, and CD34⁺ cells (only if CD34⁺ content was <80%, otherwise used directly) were enriched immunomagnetically using an EasySep CD34 Human Positive Selection Kit (STEMCELL Technologies). Purity was verified by restaining isolated cells with an allophycocyanin (APC)-labeled anti-CD34 antibody (BD Biosciences) and analyzed on a BD FACSCalibur flow cytometer (BD Biosciences), as described.^{40-44 (link)}